Company Filing History:
1 out of 8 
1 out of 2 
1 out of 1 Years Active: 2015-2025
Title: Innovations by Josep Maria Suñé Negre
Introduction
Josep Maria Suñé Negre is a notable inventor based in Barcelona, Spain. He has made significant contributions to the field of pharmaceuticals, particularly in the development of sustained release compositions and gel formulations. With a total of 3 patents, his work has the potential to impact the treatment of various medical conditions.
Latest Patents
One of his latest patents is focused on sustained release compositions comprising micronized tolcapone. This invention relates to a sustained release tablet that includes micronized tolcapone, a release retardant, and a binder. The tablet is designed for the prevention and/or treatment of transthyretin-associated amyloidosis. The patent also outlines a method for administering the tablet to subjects in need, as well as a pharmaceutical composition for the same purpose.
Another significant patent involves gel compositions. This invention provides a gel combination that includes polycarbophil, polyvinylpirrolidone, glycerine, and propylene glycol. The specific weight ratios of these components result in high bioadhesivity and bioavailability of the active ingredient, while minimizing toxic adverse effects. The patent also covers transparent compositions and processes for their preparation, emphasizing their use as medicaments.
Career Highlights
Josep has worked with several companies throughout his career, including Som Innovation Biotech, S.L. and Laboratorios Ojer Pharma, S.L. His experience in these organizations has contributed to his expertise in pharmaceutical innovations.
Collaborations
He has collaborated with notable coworkers such as Anna Nardi Ricart and Núria Reig Bolaño. These partnerships have likely enhanced his research and development efforts in the pharmaceutical field.
Conclusion
Josep Maria Suñé Negre's contributions to pharmaceutical innovations through his patents demonstrate his commitment to advancing medical treatments. His work continues to influence the industry and improve patient care.